Moving forward, we anticipate the development of both isozyme and pan-specific modulators targeting GALNT7 will yield new inhibitors, conceptually related to the widespread use of drugs targeting protein kinases, to provide a new class of therapeutics to treat prostate cancer. The gene discussed is WEE1; the disease is prostate cancer.